SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH

Yi Luo, Samir Wadhawan, Alex Greenfield, Benjamin E. Decato, Abdul M. Oseini, Rebecca Collen, Diane E. Shevell, John Thompson, Gabor Jarai, Edgar D. Charles, Arun J. Sanyal – 19 January 2021 – Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes.

Trials & Tribulations of Liver Transplantation‐ are trials now prohibitive without surrogate endpoints?

James Richards, Alex Gimson, Yexin Joh, Christopher J.E. Watson, James Neuberger – 18 January 2021 – During the past 5 decades, liver transplantation has moved from its pioneering days where success was measured in days to a point where it is viewed as a routine part of medical care. Despite this progress, there are still significant unmet needs and outstanding questions that need addressing in clinical trials to improve outcomes for patients.

Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD

Kara Wegermann, Melanie E. Garrett, Jiayin Zheng, Andrea Coviello, Cynthia A. Moylan, Manal F. Abdelmalek, Shein‐Chung Chow, Cynthia D. Guy, Anna Mae Diehl, Allison Ashley‐Koch, Ayako Suzuki – 17 January 2021 – The development of fibrosis in nonalcoholic fatty liver disease (NAFLD) is influenced by genetics, sex, and menopausal status, but whether genetic susceptibility to fibrosis is influenced by sex and reproductive status is unclear.

Subscribe to